[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605639":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":113,"collaborators":11,"id":115,"slug":11,"hasResults":116,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":11,"eligibilityCriteria":120,"healthyVolunteers":116,"sex":121,"minAge":122,"maxAge":11,"enrollmentInfo":123,"targetDuration":11,"studyType":126,"phases":127,"briefSummary":129,"conditions":130,"keywords":140,"overallStatus":33,"whyStopped":11,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":164},{"fullName":5,"class":6},"RayzeBio, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation, Dose Expansion","EXPERIMENTAL",null,[13],"Drug: RYZ401",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","RYZ401","Ac-225",[9],[21],{"name":22,"affiliation":5,"role":23},"Ye Yuan, MD","STUDY_DIRECTOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":11,"email":29},"RayzeBio Clinical Trials","CONTACT","+1 619 657 0057","clinicaltrials@rayzebio.com",[31,44,53,62,67,76,85,94,104],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":11},"Research Facility","RECRUITING","Iowa City","Iowa","52242","United States",{"type":39,"coordinates":40},"Point",[41,42],-91.53017,41.66113,{"lat":42,"lon":41},{"facility":32,"status":33,"city":45,"state":46,"zip":47,"country":37,"cosmosGeoPoint":48,"geoPoint":52,"contacts":11},"Lexington","Kentucky","40536",{"type":39,"coordinates":49},[50,51],-84.47772,37.98869,{"lat":51,"lon":50},{"facility":32,"status":33,"city":54,"state":55,"zip":56,"country":37,"cosmosGeoPoint":57,"geoPoint":61,"contacts":11},"St Louis","Missouri","63104",{"type":39,"coordinates":58},[59,60],-90.19789,38.62727,{"lat":60,"lon":59},{"facility":32,"status":33,"city":54,"state":55,"zip":63,"country":37,"cosmosGeoPoint":64,"geoPoint":66,"contacts":11},"63110",{"type":39,"coordinates":65},[59,60],{"lat":60,"lon":59},{"facility":32,"status":33,"city":68,"state":69,"zip":70,"country":37,"cosmosGeoPoint":71,"geoPoint":75,"contacts":11},"Columbus","Ohio","43210",{"type":39,"coordinates":72},[73,74],-82.99879,39.96118,{"lat":74,"lon":73},{"facility":32,"status":33,"city":77,"state":78,"zip":79,"country":37,"cosmosGeoPoint":80,"geoPoint":84,"contacts":11},"Nashville","Tennessee","37232",{"type":39,"coordinates":81},[82,83],-86.78444,36.16589,{"lat":83,"lon":82},{"facility":32,"status":33,"city":86,"state":87,"zip":88,"country":37,"cosmosGeoPoint":89,"geoPoint":93,"contacts":11},"Salt Lake City","Utah","84112",{"type":39,"coordinates":90},[91,92],-111.89105,40.76078,{"lat":92,"lon":91},{"facility":32,"status":33,"city":95,"state":96,"zip":97,"country":98,"cosmosGeoPoint":99,"geoPoint":103,"contacts":11},"Toronto","Ontario","M5G 2C4","Canada",{"type":39,"coordinates":100},[101,102],-79.39864,43.70643,{"lat":102,"lon":101},{"facility":32,"status":33,"city":105,"state":106,"zip":107,"country":98,"cosmosGeoPoint":108,"geoPoint":112,"contacts":11},"Montreal","Quebec","H3T 1E2",{"type":39,"coordinates":109},[110,111],-73.58781,45.50884,{"lat":111,"lon":110},{"type":114,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100605639",false,"NCT07165132","Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.","Phase 1 First-in-Human, Dose Escalation and Dose Expansion Study of RYZ401, a Novel Radiopharmaceutical Therapy Labeled With Actinium-225, in Subjects With Neuroendocrine Tumors and Other Solid Tumors Expressing Somatostatin Receptors.","Inclusion criteria:\n\n* At least 18 years old at the time of signing the main study informed consent form (ICF).\n* Histologically confirmed:\n\nDose Escalation (all cohorts): Grades 1-3 WD, metastatic or locally advanced and unresectable NET at any primary site, including, but not limited to, GI, pancreatic, lung, thyroid, breast, urogenital, and adrenal tumors.\n\n* Dose Expansion Cohort A: Grades 1-3 WD, metastatic or locally advanced and unresectable GEP-NETs\n* Dose Expansion Cohort B: metastatic or locally advanced and unresectable tumors known to frequently express SSTR, limited to the following indications:\n\n  * WD NETs (Grades 1-3) from primary sites other than gastrointestinal and pancreatic (including, but not limited to, lung, thyroid, breast, urogenital, and adrenal tumors) Meningioma (Grades 1-3)\n\n    * SSTR-positive disease, as assessed by SSTR-PET imaging\n    * Adequate renal, hematologic and hepatic function\n\nExclusion criteria:\n\n* Prior RPT, including Lu-177.\n* Prior solid organ or bone marrow transplantation.\n* Use of chronic systemic steroid therapy.\n* Significant cardiovascular disease\n* Resistant hypertension\n* Uncontrolled diabetes\n* Prior history of liver cirrhosis\n* HIV, hepatitis B infection or known active hepatitis C virus infection.\n\nNote: Additional criteria may apply and will be assessed by the study site","ALL","18 Years",{"count":124,"type":125},104,"ESTIMATED","INTERVENTIONAL",[128],"PHASE1","The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.",[131,132,133,134,135,136,137,138,139],"GEP-NET","Gastroenteropancreatic Neuroendocrine Tumor","Gastroenteropancreatic Neuroendocrine Tumor Disease","Neuroendocrine Tumors","Carcinoid","Carcinoid Tumor","Pancreatic NET","Solid Tumor","Somatostatin Receptor",[134,141,131,142,132,143,144,145,138,146,147,148,149,150,151,152,153,154],"SSTR+","Targeted Radiotherapy","Actinium","Ac 225","PRRT","Somatostatin Receptors","Radiopharmaceutical","BMS","Bristol Myers Squibb","Rayze","SSTR","RayzeBio","Well-differentiated NET","WD NETs","2026-06-08",{"date":157,"type":158},"2026-06-09","ACTUAL",{"date":160,"type":158},"2025-12-03",{"date":162,"type":125},"2033-04",{"name":5,"class":6},9]